FDA Targets Unapproved GLP-1 Sales; HIMS-US Plunges Over 14%

The U.S. Food and Drug Administration (FDA) has signaled aggressive enforcement against unapproved compounded GLP-1 drugs, prompting a 12.6% drop in HIMS-US after-hours. The agency warned that companies marketing these drugs—often through Hims & Hers and other pharmacies—as alternatives to approved therapies violate its authority and put consumers at risk due to unverified quality, safety, and efficacy. Hims & Hers, which launched an oral semaglutide combination pill for weight management at $49 per month, faces a regulatory headwind as the FDA clarified it cannot claim these products are equivalent to or approved by the agency. Novo Nordisk characterized the offering as “unauthorized, false, and untested counterfeit,” vowing legal and regulatory actions against “illegally large-scale compounding.” The company maintains its platform expands personalized weight management options beyond injections, emphasizing accessibility and tailored dosing. However, the FDA’s escalated approach, including seizure and injunction tools, could limit future growth and investor confidence in the remote health segment.